Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT03571373

PIBD-SETQuality: the Inception Cohort and Safety Registry

PIBD-SETQuality: the Inception Cohort and Safety Registry — Recruiting • Rheumatology • NCT03571373.

📅 11 Aug 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT03571373
Sponsor
Erasmus Medical Center
Start
2017-01-03
ClinicaliQ Trial Snapshot
  • PIBD-SETQuality: the Inception Cohort and Safety Registry — Recruiting • Rheumatology • NCT03571373.
  • What is being tested: Effectiveness and safety of current treatment strategies for pediatric-onset inflammatory bowel disease (IBD) in routine clinical practice, with correlation to individual patient risk factors.
  • Patient eligibility overview: Children and young people with newly diagnosed or established pediatric-onset inflammatory bowel disease receiving standard care across participating UK healthcare centres.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this study is to analyse effectiveness and safety signals of current treatment strategies in routine practice for patients with pediatric-onset inflammatory bowel disease (PIBD) and to correlate this to their individual risk factors.

Eligibility Snapshot
  • Inception cohort: Newly diagnosed patient,

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Osteoarthritis: Care and Management (NICE CG177)
Rheumatology · 27 Mar 2026
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before…
View guideline →
Podcast
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 00:16:21 · 03 Apr 2026
JAK inhibitors target the JAK-STAT pathway, interrupting intracellular cytokine signalling across several inflammatory diseases. ORAL Surveillance reshaped risk assessment after higher rates…
Listen →
Guideline
2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis in Rheumatology. Use it to review current recommendation wording,…
View guideline →
Guideline
2023 EULAR Recommendations for the Management of Gout
Rheumatology · 30 Mar 2026
This EULAR guideline addresses 2023 EULAR Recommendations for the Management of Gout in Rheumatology. Use it to review current recommendation wording, eligibility…
View guideline →
Guideline
Axial Spondyloarthritis: Diagnosis and Management (NICE NG65)
Rheumatology · 27 Mar 2026
Refer adults to rheumatology if they present with chronic back pain (≥3 months) plus any of: inflammatory back pain features, elevated inflammatory…
View guideline →
Webinar
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Rheumatology · 0.5 · 05 Apr 2026
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL Surveillance safety signals, cardiovascular…
Watch webinar →